Constitutive activity in melanocortin-4 receptor: biased signaling of inverse agonists

Ya-Xiong Tao1

  • 1Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA.

Insights

The melanocortin-4 receptor (MC4R) regulates energy balance. Some MC4R drugs act differently in distinct signaling pathways, acting as agonists in one and inverse agonists in another, impacting obesity research.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Endocrinology

Background:

  • The melanocortin-4 receptor (MC4R) is a key regulator of energy homeostasis, influencing appetite and metabolism.
  • MC4R activity is modulated by hormones and ligands like Agouti-related peptide (AgRP).
  • Mutations in MC4R can lead to altered basal activity, potentially causing obesity.

Purpose of the Study:

  • To investigate the signaling bias of MC4R ligands and mutations.
  • To explore the differential activation of MC4R in the Gs-cAMP and ERK1/2 pathways.
  • To understand the implications of biased signaling in energy balance and obesity.

Main Methods:

  • Assessed the activity of AgRP and small-molecule antagonists in Gs-cAMP and ERK1/2 signaling pathways.
  • Investigated MC4R mutations for constitutive activation in different signaling pathways.
  • Utilized biochemical assays to measure receptor activity.

Main Results:

  • AgRP and antagonists act as inverse agonists in the Gs-cAMP pathway but as agonists in the ERK1/2 pathway, demonstrating biased agonism.
  • Certain MC4R mutations cause constitutive activation in the ERK1/2 pathway without affecting the Gs-cAMP pathway, indicating biased receptors.
  • These findings reveal a novel mechanism of MC4R regulation.

Conclusions:

  • MC4R ligands and mutations can exhibit biased signaling, differentially activating downstream pathways.
  • Biased signaling in MC4R may contribute to energy homeostasis dysregulation and obesity.
  • Further research is needed to elucidate the physiological relevance and therapeutic potential of biased MC4R signaling.

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.5K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.8K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.1K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
8.3K